Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
NCT04339777Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic hematopoietic stem cells in inborn errors of immunity (IEI) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Sustained donor engraftment at 100 days. Started Sep 2020; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
inborn errors of immunity (IEI)
Beyond the preview
Go deeper on NCT04339777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339777.